Surgery News | Medical XPRT

Scivita Medical Raises Nearly RMB0.4 Billion in Series a Funding Round and Strives to Build a World-leading Platform for Innovative Products in Endoscope and Related Fields

Scivita Medical Technology Co., Ltd. ('Scivita Medical*) today announced that it has raised nearly RMB0.4 Billion in Series A funding round, which has become one of the highest financing projects in the field of endoscope in China in recent years. The investment was jointly led by GL Ventures and Lilly Asia Ventures with contribution from Matrix Partners China, Medtronic, Chengwei Capital and ...

Apr. 26, 2021

By Scivita Medical Technology Co., Ltd.

BioStable Science & Engineering Announces CE Mark Approval for the HAART 200 Aortic Annuloplasty Device & Surpasses 1,000 Patients Treated Worldwide with the HAART Devices

BioStable Science & Engineering, Inc., (“BioStable”) announced today the company has received CE Mark approval for the HAART 200 Aortic Annuloplasty Device for use during bicuspid aortic valve repair. With CE Mark approval of both the HAART 300 and HAART 200 Aortic Annuloplasty Devices, BioStable will be able to offer surgeons within the European Union a comprehensive portfolio of ...

Apr. 21, 2021

By BioStable Science & Engineering, Inc.

Evaxion Biotech Announces Q4 and Full-Year 2020 Financial Results and Provides Business Update

Successfully completed initial public offering on U.S. Nasdaq in February 2021, raising gross proceeds of $30 million Clinical development on track with dosing of first patient in Phase 1/2a melanoma trial of cancer vaccine EVX-02 Cash reserves of $5.8 million at December 31, 2020 plus funds from IPO provide funding for at least 12 months from the date of completion of the IPO COPENHAGEN, ...

Apr. 6, 2021

By Evaxion Biotech A/S

India’s HealthPlix raises $13.5 million to help doctors treat patients more efficiently

There are fewer than 300,000 doctors in India actively practicing medicine. They serve hundreds of millions of patients who suffer from chronic illness in the world’s second-most populous nation. A doctor only has a few minutes to spend on a patient, remember the past diagnosis by glancing at their record and formulate a plan of management. HealthPlix, a Bangalore-based startup, believes ...

Mar. 31, 2021

By HealthPlix Technologies Private Limited

Dicerna’s GalXC-Plus™ RNAi Technology Delivers Target Knockdown Across CNS and to Specific CNS Cell Types in Preclinical Studies

Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced new data from preclinical studies of its GalXC-Plus™ RNAi technology demonstrating its potential to deliver deep and sustained messenger RNA (mRNA) knockdown against prespecified gene ...

Mar. 30, 2021

By Dicerna Pharmaceuticals, Inc.

Merck Announces Acquisition of Alydia Health on behalf of its Planned Spinoff of Organon

Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Alydia Health announced today that they have entered into a definitive agreement pursuant to which, after the intended Merck spinoff of Organon, Organon will acquire Alydia Health. Alydia Health is a commercial-stage medical device company focused on preventing maternal morbidity and mortality caused by postpartum ...

Mar. 30, 2021

By Merck Sharp & Dohme Corp., a Subsidiary of Merck & Co., Inc.

Aspect Biosystems And Jsr Corporation Enter Collaboration To Develop Bioprinted Vascularized Tissues For Regenerative Medicine

Aspect Biosystems, a privately held biotechnology company pioneering the development of bioprinted therapeutics, is pleased to announce a new joint development program with JSR Corporation, a global leader in advanced materials innovation. This collaboration builds on the existing partnership between the two companies and will see the combining of Aspect’s proprietary microfluidic 3D ...

Mar. 30, 2021

By Aspect Biosystems Ltd.

Merck Receives Complete Response Letter From US FDA for Supplemental Biologics License Application (sBLA) for KEYTRUDA® (pembrolizumab) in High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC)

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding Merck’s supplemental Biologics License Application (sBLA) seeking approval for KEYTRUDA, the company’s anti-PD-1 therapy, for the treatment of patients with high-risk early-stage triple-negative ...

Mar. 29, 2021

By Merck Sharp & Dohme Corp., a Subsidiary of Merck & Co., Inc.

bit.bio CEO Dr Mark Kotter speaking about challenging biology at the TEDxCambridgeUniversity ‘Untangling networks’ event

On Saturday 20 March 2021, bit.bio CEO and founder Mark Kotter was a speaker at the TEDxCambridgeUniversity ‘Untangling networks’ event. Dr Kotter was speaking about his work as a neurosurgeon, stem cell biologist and an entrepreneur. Many of the conditions he faces as a doctor, whether they are cancers, genetic or degenerative conditions, need more than a scalpel and screws or ...

Mar. 26, 2021

By bit.bio

Joint FDA Advisory Committee Votes on Application for Tanezumab for the Treatment of Osteoarthritis Pain

Pfizer Inc. (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) today announced the outcome of the U.S. Food and Drug Administration (FDA) Joint Arthritis Advisory Committee and Drug Safety and Risk Management Advisory Committee on tanezumab. There was a single voting question focused on whether the proposed risk evaluation and mitigation strategy (REMS) for tanezumab will ensure its benefits ...

Mar. 25, 2021

By Eli Lilly and Company

PhotoniCare Announces Rebranding of First-in-Class Technology for Imaging the Middle Ear, Now called OtoSight Middle Ear Scope

PhotoniCare, Inc., a company dedicated to revolutionizing healthcare by providing healthcare providers with better diagnostic tools, today announced that it is rebranding its middle ear scope to OtoSight™ Middle Ear Scope (formerly TOMi™ Scope). In preparation for the 2021 commercial launch, the OtoSight™ Middle Ear Scope brand name is well-positioned to convey the ...

Mar. 25, 2021

By PhotoniCare Inc.

Moffitt Cancer Center Advances Patient Standard of Care by Introducing Needleless Blood Draws

Moffitt Cancer Center has adopted a new needle-free method of blood collection for patients in treatment who often need to undergo repeated needle sticks in a day, becoming the first cancer center in Florida to offer this pain-free technology as part of its world-class cancer care. In its continuing efforts of being at the forefront of innovation, last year the cancer center piloted the ...

Mar. 24, 2021

By Velano Vascular

Fractyl Announces First Patient Enrolled in Pivotal Study of Novel Procedural Therapy Revita® DMR for Type 2 Diabetes

Fractyl Laboratories Inc. (Fractyl), a life sciences company dedicated to developing novel therapeutic interventions aimed at reversing the metabolic disease epidemic, today announced the enrollment of the first patient in a pivotal clinical trial of Revita® DMR for patients with type 2 diabetes. The trial, called REVITA-T2Di, will evaluate the ability of a single Revita DMR treatment to ...

Mar. 22, 2021

By Fractyl Laboratories Inc.

Vaccitech Doses First Patient in HPV001, a Phase 1/2 Clinical Trial of VTP-200 Immunotherapeutic for High-risk Persistent HPV Infection

Vaccitech Ltd, a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer, today announced the dosing of the first patient as part of the HPV001 clinical study. HPV001 is a randomized, placebo-controlled Phase 1/2 clinical trial designed to evaluate the safety and ...

Mar. 18, 2021

By Vaccitech Limited

UroGen Pharma Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Corporate Developments

UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced financial results for the fourth quarter and full year ended December 31, 2020 and provided an overview of the Company’s recent developments. “2020 was a pivotal year for UroGen with the launch of ...

Mar. 18, 2021

By UroGen Pharma, Inc.

Inspire Medical Systems, Inc. Announces FDA Approval of Two-Incision Implant Procedure

Inspire Medical Systems, Inc. (NYSE: INSP) (“Inspire”), a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea, today announced receipt of U.S. Food and Drug Administration (“FDA”) approval for an improved surgical implant procedure that eliminates one incision ...

Mar. 15, 2021

By Inspire Medical Systems, Inc.

Asensus Surgical, Inc. Reports Operating and Financial Results for the Fourth Quarter and Full Year 2020

Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced its operating and financial results for the fourth quarter and full-year 2020. Recent Highlights Senhance Surgical System received expanded 510(k) clearance for general ...

Mar. 11, 2021

By Asensus Surgical US, Inc.

AbCellera-Discovered Bamlanivimab Together with Etesevimab Reduced Hospitalizations and Prevented Death in Phase 3 Trial for Early COVID-19

AbCellera (Nasdaq: ABCL) today announced that bamlanivimab (LY-CoV555) 700 mg, a human antibody discovered by AbCellera and developed with Eli Lilly and Company (Lilly), and etesevimab 1400 mg (LY-CoV16) together reduced COVID-19-related hospitalizations and deaths by 87% in high-risk patients recently diagnosed with COVID-19. These results mark the second positive Phase 3 trial readout for ...

Mar. 10, 2021

By AbCellera Biologics Inc.

Lyra Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results, Provides Corporate Update

Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat (ENT) diseases, today reported financial results for the fourth quarter and full year ended December 31, 2020 and provided a corporate update. Key Fourth ...

Mar. 9, 2021

By Lyra Therapeutics, Inc.

CMS Consolidates SINUVA Sinus Implant Coverage Under a Distinct Code, J7402, and Publishes an ASP Clarifying Payment and Easing Payer Coverage Adjudication

Intersect ENT®, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced that the Centers for Medicare and Medicaid Services (CMS) published an average selling price (ASP) for the Company’s SINUVA sinus implant, providing predictability, transparency, and confidence of reimbursement for ...

Mar. 8, 2021

By Intersect ENT, Inc.